Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases

被引：37

作者：

Bonomo, RA ^{[1
]}

Rudin, SA ^{[1
]}

Shlaes, DM ^{[1
]}

机构：

[1] CASE WESTERN RESERVE UNIV,UNIV HOSP CLEVELAND,GERIATR CARE CTR,DEPT MED,CLEVELAND,OH 44120

来源：

FEMS MICROBIOLOGY LETTERS | 1997年 / 148卷 / 01期

关键词：

inhibitor-resistant beta-lactamase; piperacillin; tazobactam; ESCHERICHIA-COLI; SULBACTAM; MUTATIONS;

D O I：

10.1016/S0378-1097(97)00013-X

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The beta-lactam beta-lactamase inhibitor combinations (ampicillin/clavulanate, ampicillin/sulbactam, ticarcillin/clavulanate and piperacillin/tazobactam) were tested against selected inhibitor-resistant class A beta-lactamases of the TEM and OHIO-1 varieties. Minimum inhibitor concentrations (MIC) revealed that the Escherichia coli DH5 alpha transconjugate strains that possessed the OHIO-1 beta-lactamase, Met(69)Ile mutant of the OHIO-1 beta-lactamase, TEM-30 (Arg(244)Ser) and TEM-31 (Arg(244)Cys) beta-lactamase were most susceptible to piperacillin and piperacillin/tazobactam. Kinetic experiments with each beta-lactamase demonstrated that tazobactam was 10-25-fold more potent than clavulanate or sulbactam against TEM-30 and TEM-31 beta-lactamase. Tazobactam was also as effective as clavulanate against the Met(69)Ile mutant of the OHIO-1 beta-lactamase. Among the clinically available beta-lactams and beta-lactamase inhibitors, piperacillin/tazobactam appears to be the most potent combination against selected inhibitor-resistant strains of TEM and OHIO-1 beta-lactamase.

引用

页码：59 / 62

页数：4

共 13 条

[1] A STANDARD NUMBERING SCHEME FOR THE CLASS-A BETA-LACTAMASES
AMBLER, RP
COULSON, AFW
FRERE, JM
GHUYSEN, JM
JORIS, B
FORSMAN, M
LEVESQUE, RC
TIRABY, G
WALEY, SG
[J]. BIOCHEMICAL JOURNAL, 1991, 276 : 269 - 270
[2] BELAAOUAJ A, 1994, FEMS MICROBIOL LETT, V120, P75
[3] CHARACTERIZATION OF A NEW TEM-TYPE BETA-LACTAMASE RESISTANT TO CLAVULANATE, SULBACTAM, AND TAZOBACTAM IN A CLINICAL ISOLATE OF ESCHERICHIA-COLI
BLAZQUEZ, J
BAQUERO, MR
CANTON, R
ALOS, I
BAQUERO, F
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (10) : 2059 - 2063
[4] BETA-LACTAMASE MUTATIONS FAR FROM THE ACTIVE-SITE INFLUENCE INHIBITOR BINDING
BONOMO, RA
DAWES, CG
KNOX, JR
SHLAES, DM
[J]. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1995, 1247 (01): : 121 - 125
[5] OHIO-1 BETA-LACTAMASE RESISTANT TO MECHANISM-BASED INACTIVATORS
BONOMO, RA
CURRIEMCCUMBER, C
SHLAES, DM
[J]. FEMS MICROBIOLOGY LETTERS, 1992, 92 (01) : 79 - 82
[6] COMPLEMENTARY ROLES OF MUTATIONS AT POSITION-69 AND POSITION-242 IN A CLASS-A BETA-LACTAMASE
BONOMO, RA
DAWES, CG
KNOX, JR
SHLAES, DM
[J]. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1995, 1247 (01): : 113 - 120
[7] Implication of Ile-69 and Thr-182 residues in kinetic characteristics of IRT-3 (TEM-32) beta-lactamase
Farzaneh, S
Chaibi, EB
Peduzzi, J
Barthelemy, M
Labia, R
Blazquez, J
Baquero, F
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) : 2434 - 2436
[8] MOLECULAR CHARACTERIZATION OF 9 DIFFERENT TYPES OF MUTANTS AMONG 107 INHIBITOR-RESISTANT TEM BETA-LACTAMASES FROM CLINICAL ISOLATES OF ESCHERICHIA-COLI
HENQUELL, C
CHANAL, C
SIROT, D
LABIA, R
SIROT, J
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (02) : 427 - 430
[9] DETERMINANTS OF THE ACTIVITY OF BETA-LACTAMASE INHIBITOR COMBINATIONS
LIVERMORE, DM
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 : 9 - 21
[10] COMPARATIVE ACTIVITIES OF CLAVULANIC ACID, SULBACTAM, AND TAZOBACTAM AGAINST CLINICALLY IMPORTANT BETA-LACTAMASES
PAYNE, DJ
CRAMP, R
WINSTANLEY, DJ
KNOWLES, DJC
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) : 767 - 772

← 1 2 →